This study includes our first 100 patients who received local prostatic hyperthermia treatment for benign prostatic hyperplasia. Subjective symptoms such as nycturia, stream, urgency, and objective facts like urine flow and postmicturition residue were monitored before treatment and 3 months after. The clinical (subjective) symptoms improved in 76 patients. Urinary flow increased in 63 patients, and the postmicturition urinary residue decreased in 32 patients. We were able to show that local prostatic hyperthermia is a valid option for the treatment of benign prostatic hyperplasia although it is still too early to assess the long-term results.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000471650DOI Listing

Publication Analysis

Top Keywords

treatment benign
12
benign prostatic
12
prostatic hyperplasia
12
hyperthermia treatment
8
100 patients
8
local prostatic
8
prostatic hyperthermia
8
subjective symptoms
8
prostatic
5
patients
5

Similar Publications

Background: Current diagnostic imaging modalities have limited ability to differentiate between malignant and benign pancreaticobiliary disease, and lack accuracy in detecting lymph node metastases. F-Prostate-Specific Membrane Antigen (PSMA) PET/CT is an imaging modality used for staging of prostate cancer, but has incidentally also identified PSMA-avid pancreatic lesions, histologically characterized as pancreatic ductal adenocarcinoma (PDAC). This phase I/II study aimed to assess the feasibility of F-PSMA PET/CT to detect PDAC.

View Article and Find Full Text PDF

This article provides an overview of treatment approaches for chronic kidney disease (CKD) in patients with IgA nephropathy (IgAN). IgAN is the most common primary glomerulonephritis and results from an autoimmune reaction to aberrantly glycosylated immunoglobulin A (IgA) antibodies. Although historically considered largely benign, it is now recognized that a significant percentage of patients develop dialysis-dependent kidney disease over the years.

View Article and Find Full Text PDF

Cystic breast masses are a common entity encountered by breast radiologists. The imaging features of benign and malignant cystic masses may overlap, causing confusion and miscategorization with the potential to produce diagnostic delay and harm. This article provides a review of key differentiating imaging features that help guide appropriate mass characterization and treatment.

View Article and Find Full Text PDF

We aimed to determine the prevalence of gastroesophageal reflux disease (GERD) and oropharyngeal dysphagia as explanatory diagnoses, risk factors for acid suppression treatment, and risk factors for repeat hospital visit in infants hospitalized after brief resolved unexplained event (BRUE) using a multicenter pediatric database. We performed a multicenter retrospective database study of infants admitted with BRUE in the Pediatric Health Information System between 2016 and 2021. Data included diagnostic testing, explanatory diagnoses, treatment with acid suppression, and related repeat hospital visits within 6 months.

View Article and Find Full Text PDF

Peficitinib suppresses diffuse-type tenosynovial giant cell tumor by targeting TYK2 and JAK/STAT signaling.

Sci China Life Sci

January 2025

Institute of Cardiovascular Sciences, School of Basic Medical Sciences, Peking University Health Science Center; Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, 100191, China.

Diffuse-type tenosynovial giant cell tumor (dTGCT) is a destructive but rare benign proliferative synovial neoplasm. Although surgery is currently the main treatment modality for dTGCT, the recurrence risk is up to 50%. Therefore, there is a great need for effective drugs against dTGCT with minor side effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!